SCHEMBL14477832

SCHEMBL14477832

CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](COC1OC(CO)C(O)C(O)C1O)NC(=O)NCCCCCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SELP P16109 7/20 0.43
▸ SELL P14151 3/20 0.43
▸ SELE P16581 3/20 0.43
▸ APP P05067 1/20 0.43
▸ SYNJ2 O15056 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ ALPL P05186 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ ALPI P09923 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ ALPG P10696 1/20 0.42
▸ PABPC1 P11940 1/20 0.42
▸ RECQL P46063 1/20 0.42
▸ GALK1 P51570 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ CASP6 P55212 1/20 0.42
▸ MCL1 Q07820 1/20 0.42
▸ RIN1 Q13671 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20786855 0.90 APP (0.50) SELPSELLSELEAPPCETP
SCHEMBL14477845 0.90 APP (0.50) SELPSELLSELEAPPCETP
SCHEMBL20786854 0.90 APP (0.50) SELPSELLSELEAPPCETP
SCHEMBL14477842 0.90 APP (0.50) SELPSELLSELEAPPCETP
SCHEMBL14477841 0.90 APP (0.50) SELPSELLSELEAPPCETP
SCHEMBL2615729 0.89 SELP (0.51) SELPSELLSELEAPPSYNJ2
SCHEMBL2627817 0.89 SELP (0.51) SELPSELLSELEAPPSYNJ2
SCHEMBL2615749 0.89 SELP (0.51) SELPSELLSELEAPPSYNJ2
SCHEMBL15603823 0.89 SELP (0.51) SELPSELLSELEAPPSYNJ2
SCHEMBL12738925 0.89 SELP (0.51) SELPSELLSELEAPPSYNJ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853173-B2 Synthetic glycolipid and use thereof RIKEN (JP) 2014-10-07 — — US disclosed
US-20130005669-A1 NOVEL SYNTHETIC GLYCOLIPID AND USE THEREOF RIKEN (JP) 2013-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005669-A1 NOVEL SYNTHETIC GLYCOLIPID AND USE THEREOF IFNG, IFNAR1, UGCG SELP 1317/4885SELL 695/4885SELE 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback